GRACE Trial: Acupuncture Integrated into Sickle Cell Disease Treatment

Sickle cell disease (SCD) affects millions of people worldwide and constitutes one of the main causes of chronic pain of hematologic origin. Conventional management depends largely on opioids, which exposes patients to significant risks of tolerance, dependence, and cumulative adverse effects. In this scenario, the GRACE pragmatic trial — conducted under the umbrella of the NIH Collaboratory, the HEAL Initiative, and NCCIH — has the proposal of evaluating the integration of medical acupuncture and guided relaxation as complementary strategies for pain control in specialized clinics. This news focuses on the recent qualitative publication (Ibemere et al., 2026) on barriers and facilitators of implementation of the trial; the primary efficacy results of GRACE have not yet been published in a peer-reviewed journal and will be the subject of a future news item.

The pragmatic design of the study is especially relevant because it investigates the effectiveness of the interventions within the real routine of health services, and not under controlled laboratory conditions. This means that the results more faithfully reflect the challenges and opportunities that physicians and teams face when incorporating medical acupuncture into the care flow. A recent qualitative analysis, published in Pain Management Nursing (Ibemere et al., 2026), interviewed 13 clinical professionals from the participating centers to map the main barriers and facilitators of this integration.

Among the barriers identified, the following stand out: interruptions in the clinics’ workflow, the need for more flexible schedules for acupuncture sessions, insufficient physical space for visits, additional administrative burden, knowledge gaps among professionals about medical acupuncture, and hesitation of some patients in the face of an unfamiliar modality. These findings reinforce that clinical evidence, although necessary, is not sufficient on its own — implementation requires structural and cultural changes in the hospital environment.

The GRACE trial represents an important advance in the way clinical research approaches the integration of evidence-based complementary therapies into conventional care. By systematically documenting both obstacles and practical solutions, the study provides a roadmap that can be adapted by health services in different contexts — including regions with high prevalence of sickle cell disease, where medical acupuncture is increasingly recognized as a formal specialty. Following the final results of this pragmatic trial will be essential to consolidate the evidence base that supports the use of medical acupuncture in the management of chronic pain of hematologic origin.